by 
The acute bacterial skin and skin structure infections (ABSSSI) market comprises of products used to treat various types of bacterial skin infections such as cellulitis, abscesses, and infected wounds that require medical intervention. Antibiotics and drugs used in the treatment of ABSSSI help reduce pain, swelling and cure infections caused by bacteria. With rising cases of drug resistance to common antibiotics, pharmaceutical companies are focusing on development of novel and advanced antibiotics drugs to effectively manage difficult-to-treat bacterial skin infections.
The global Acute Bacterial Skin and Skin Structure Infections market is estimated to be valued at US$ 3,466.6 Mn in 2024 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030.
Advancements in antibiotic development have aided in improving treatment outcomes for patients suffering from complicated skin infections. Growing bacterial resistance and increasing incidence of skin infections due to rising prevalence of chronic diseases such as diabetes fuel market growth.
Key Takeaways
Key players operating in the ABSSSI market are Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc. These companies are focusing on new product development and launches to strengthen their market position.
The market provides opportunities for growth owing to increasing healthcare expenditure and rising demand for generic drugs for cost-effective treatment of bacterial infections. Additionally, technological advancements including development of novel drug delivery systems have augmented treatment outcomes.
Market drivers:
Increasing prevalence of chronic diseases such as diabetes that weaken the immune system and make patients susceptible to bacterial skin infections is a major growth driver. According to WHO, the global diabetes prevalence in adults aged 18 years and older has risen from 4.7% in 1980 to 8.5% in 2014. Moreover, growing elderly population prone to bacterial infections also fuels market expansion.
Current Challenges in Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market
The ABSSSI market faces several challenges which hinders its growth. Firstly, the rising antimicrobial resistance is a major obstacle. Many bacterial strains are developing resistance against existing drugs which reduces treatment effectiveness. Secondly, the complex nature of skin infections poses diagnostic challenges. It is difficult to accurately identify the causative pathogen in many cases. Misdiagnosis can lead to treatment failure or delay. Thirdly, lack of new drug approvals is an issue. Only a few novel antibiotics have entered the market in recent years. The antibiotic pipeline is not robust enough to meet future needs. Lastly, the market is price sensitive with cost containment being a key priority for payers. This puts pricing pressure on manufacturers and limits their ability to recover R&D investments. Overall, overcoming antimicrobial resistance, improving diagnostics, boosting drug pipelines and managing costs are critical challenges for the ABSSSI industry.
SWOT Analysis
Strengths: Presence of large number of generic drug manufacturers ensures drug availability and price competition. Established standard treatment guidelines aid clinical decision making.
Weaknesses: Heavy regulation delays product approvals and increases costs. Rising antimicrobial resistance reduces efficacy of existing drugs.
Opportunities: Unmet needs in certain patient segments present scope for novel drugs and formulations. Growth opportunities in developing markets with improving access to healthcare.
Threats: Intense competition from alternative treatments threatens drug sales. Stringent cost control measures can squeeze profits. Tightening antibiotic stewardship programs may restrict drug usage.
Geographical Regions with Highest Market Value
The United States represents the most lucrative region for ABSSSI drugs, contributing over 35% to global market value. This is attributed to factors like high incidence of skin infections, well-established healthcare infrastructure and favorable reimbursement system. Europe is the second largest region driven by universal healthcare and awareness about proper treatment of skin disorders. However, growing economies of Asia Pacific are emerging as fast growing markets supported by expanding patient pools and increasing healthcare spending.
Fastest Growing Geographical Region
Asia Pacific region is poised to be the fastest growing market for ABSSSI therapeutics over the forecast period. This is because countries like India, China, Japan and South Korea are experiencing rapid economic development and enhancing access to modern medical services. Rising living standards, expanding medical insurance coverage and growing geriatric population susceptible to skin infections are driving the APAC ABSSSI market. Furthermore, greater focus of global pharma players on opportunities in developing Asia will accelerate the region’s market growth relative to mature Western markets.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
